Multiple Myeloma
Featured Articles
(Minneapolis Star Tribune) Aug 19, 2017 - Researchers at the Mayo Clinic and the University of Minnesota say they’re on the brink of a new era in cancer care — one in which doctors extract a patient’s white blood cells, have them genetically engineered in a lab, and put them back to become personalized cancer-fighting machines.
Read Article
(TheStreet) Aug 8, 2017 - Cellectar Biosciences, Inc., an oncology-focused, clinical stage biotechnology company, today announces its lead PDC compound, CLR 131 has achieved a median overall survival of 22.5 months to date after a single dose infusion of 12.5mCi/m2 in patients with multiple myeloma.
Read Article
Latest Articles
July 27, 2017
July 26, 2017
July 20, 2017
July 18, 2017
July 14, 2017
July 13, 2017
June 29, 2017
June 26, 2017
View More
News Commentary
Editor Image
02 Apr, 2017 | by Winston Wong, PharmD
Ok. So maybe the there was a bit of overexcitement from NantKwest's product. ...
View Comment
Editor Image
16 Jun, 2017 | by Winston Wong, PharmD
This sounds like the same play innovator manufacturers are playing in the...
View Comment
View More
OBR Green
There are no Multiple Myeloma OBR Green articles.
OBR Blog
This year's ASH Annual Meeting will be chock-full of interesting, informative, and clinically useful presentations,... Read more
November 22, 2016